## DXCM: DexCom, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.91 indicates fundamental undervaluation. Quality metrics strong (ROE 31%). Caution: momentum weakening (-2.3% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($61.86)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bearish (Bullish: 0, Bearish: 7)

**1. Levi & Korsinsky Reminds DexCom, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 26, 2025 – DXCM**
- Source: GlobeNewswire | 20251218T220817 | Bearish | Relevance: 100%
- Levi & Korsinsky, LLP is reminding investors in DexCom, Inc. (NASDAQ: DXCM) about a class action lawsuit filed against the company. The lawsuit alleges securities fraud between January 8, 2024, and September 17, 2025, claiming DexCom made unauthorized design changes to its glucose monitoring products, the G6 and G7, making them less reliable and posing health risks. Investors who suffered losses have until December 26, 2025, to request to be appointed as lead plaintiff.

**2. Halper Sadeh LLC Encourages DexCom, Inc. Shareholders to Contact the Firm to Discuss Their Rights**
- Source: GlobeNewswire | 20251218T182357 | Somewhat-Bearish | Relevance: 100%
- Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary duties to shareholders. Long-term shareholders are encouraged to contact the firm to discuss potential legal rights and options, including corporate governance reforms, fund recovery, or financial incentives. The firm handles cases on a contingent fee basis, and shareholder participation aims to improve company transparency and oversight.

**3. Halper Sadeh LLC Encourages DexCom, Inc. Shareholders to Contact the Firm to Discuss Their Rights**
- Source: GlobeNewswire | 20251218T132100 | Somewhat-Bearish | Relevance: 100%
- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary duties to shareholders. Long-term DexCom shareholders are encouraged to contact the firm to discuss potential legal rights and options, including seeking corporate governance reforms or financial incentives. Involvement by shareholders can lead to improved company policies and enhanced shareholder value.

**4. Class Action Initiated by Pomerantz LLP Concerning DexCom, Inc. – DXCM**
- Source: www.yourerie.com | 20251218T120947 | Bearish | Relevance: 100%
- Pomerantz LLP has filed a class action lawsuit against DexCom, Inc. (DXCM) and certain officers, alleging that the company made materially false and misleading statements regarding its business, operations, and compliance policies between July 26, 2024, and September 17, 2025. The lawsuit claims DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, rendering them less reliable and posing health risks, which led to significant stock price drops following FDA warnings and a critical report. Investors who purchased DexCom securities during the Class Period have until December 26, 2025, to seek appointment as Lead Plaintiff.

**5. DexCom (DXCM) Fell Due to Modest Guidance**
- Source: Insider Monkey | 20251218T100900 | Somewhat-Bearish | Relevance: 100%
- DexCom, Inc. (DXCM) shares fell despite exceeding Q2 consensus expectations, primarily due to modest guidance that failed to reflect year-to-date strength, and concerns raised by a short report regarding its G7 launch. Brown Advisory Mid-Cap Growth Strategy, which holds DXCM, noted that production issues were known and addressed, and early G7 injury rates have improved. While DXCM is not among the 30 most popular stocks among hedge funds, 71 hedge funds held positions at the end of Q3 2025, an increase from the previous quarter.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Mizuho | $78 | $75 | +4% |
| 2025-12-11 | Citigroup | $77 | $75 | +3% |
| 2025-12-02 | Morgan Stanley | $75 | $63 | +19% |
| 2025-11-25 | Evercore ISI Gr | $68 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Mizuho | main | Outperform |
| 2025-12-11 | Citigroup | main | Buy |
| 2025-12-02 | Morgan Stanley | up | Overweight |
| 2025-11-25 | Evercore ISI Gr | init | In-Line |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.14M) |
| Sells | 3 ($0.45M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 61.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Tudor Investment Cor: 17.7% (+100.0%)
- Vanguard Group Inc: 12.7% (+2.4%)
- Blackrock Inc.: 10.0% (-0.5%)
- State Street Corpora: 4.3% (-0.0%)
- BAILLIE GIFFORD & CO: 4.1% (-4.9%)

### Key Risks

1. Long-term trend broken: trading 10.8% below SMA200.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +9%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 0.91 indicates undervaluation relative to growth. Quality metrics strong (ROE 31%, margin 16%). Analyst sentiment positive (3 raises, avg +9%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $25.9B |
| Beta | 1.51 |
| 52W Range | $54.11 - $93.25 |
| Short Interest | 4.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.91 |
| Forward P/E | 26.6 |
| Current P/E | 32.0 |
| YoY Growth | 20.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 3.7% to 1.4% (-2.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.6pp (needs >4.0% for momentum thesis). MRS_5 (-1.0%) diverging from MRS_20 - short-term weakness emerging. Below SMA200 (0.89x), long-term trend not supportive. RSI neutral at 55. OFD pattern: -SBH (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.41% (CS: 64) | Neutral |
| RSI_14 | 55.4 | Neutral |
| MACD Histogram | 0.11 | Bullish |
| vs SMA20 | 1.017x | Above |
| vs SMA50 | 1.032x | Above |
| vs SMA200 | 0.892x | Below |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $66.06
- **Stop Loss:** $61.86 (6.4% risk)
- **Target:** $74.46 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 285
- **Position Value:** $18,827.10
- **Portfolio %:** 18.83%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-12 (Est: $0.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.57 | $0.61 | +7.5% |
| 2025Q2 | $0.44 | $0.48 | +8.2% |
| 2025Q1 | $0.33 | $0.32 | -2.6% |
| 2024Q4 | $0.50 | $0.45 | -9.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*